Advaxis News Releases

Date	Title and Summary	Additional Formats
May 11, 2018	Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent "Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the	PDF Version
April 23, 2018	Advaxis Announces Executive Leadership Changes Kenneth A. Berlin appointed President, CEO and Director; Dr. Andres A. Gutierrez named Chief Medical Officer; Sara Bonstein, CFO, to depart "On behalf of the Board, I would like to take this opportunity to sincerely thank Sara Bonstein and Anthony Lombardo for their valued service to the company as	PDF Version
April 17, 2018	Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting Lm platform targets common mutations in tumor driver genes "Targeting Shared Hotspot Cancer Mutations with a Listeria monocytogenes Immunotherapy Induce Potent Anti-Tumor Immunity" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused	PDF Version
April 2, 2018	Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting "ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces	PDF Version
March 26, 2018	Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018 Including Three Late-Breaking Poster Presentations PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical	PDF Version
March 13, 2018	Advaxis to Present at Upcoming March Conferences PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today that Company management will present at the following	PDF Version
March 12, 2018	Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab) Conference call to be held today at 4:30 p.m. Eastern time "We are confident in the safety and efficacy profile of axalimogene filolisbac, to date, based on our experience in over 250 patients and over 700 doses across multiple trials in HPV-associated cancers." PRINCETON, N.J.--( BUSINESS WIRE )--	PDF Version
March 9, 2018	Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018 PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results for the three months ended January 31, 2018, to	PDF Version
February 22, 2018	Advaxis Prices $20.0 Million Public Offering of Common Stock PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of its previously announced underwritten public	PDF Version
February 21, 2018	Advaxis Announces Proposed Public Offering of Common Stock PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company (“Advaxis” or the “Company”) focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to offer and sell shares of its common stock	PDF Version